Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Items 201–300 of 588
Atopic dermatitis: the new frontier
Harris, V., & Cooper, A. J. (2017) · The Medical Journal of Australia · doi:10.5694/mja17.00463 · Cited by 34
Critical Players and Therapeutic Targets in Chronic Itch
Hua, Y., Chen, W., Zhu, R., Wang, J., & Meng, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179935 · Cited by 35
Cytokines and chemokines modulation of itch.
Du, L.-X., Zhu, J.-Y., & Mi, W. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.035 · Cited by 16
Innovation in Atopic Dermatitis: From Pathogenesis to Treatment
Munera‐Campos, M., & Carrascosa, J. M. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2020.03.001 · Cited by 34
“5 mg/kg, and 2 mg/kg every 4 weeks for 12 weeks) showed decreases in pruritus; however, improvement on the clinical scales was not statistically significant.(40,42) Nemolizumab could be effective in reducing pruritus, as well as improving daily activities and work productivity,(43) with an acceptable safety profile.”
Beneficial effects of coagulase‐negative Staphylococci on Staphylococcus aureus skin colonization
Bier, K., & Schittek, B. (2021) · Experimental Dermatology · doi:10.1111/exd.14381 · Cited by 40
Impact of a Decade of Research Into Atopic Dermatitis
Arkwright, P. D., & Koplin, J. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.021 · Cited by 34
Jha, M. K., Han, Y., Liu, Z., Hara, Y., Langohr, I. M., Morel, C., Maloney, C., Piepenhagen, P. A., Xing, H., Bodea, C. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.05.011 · Cited by 41
Mihara, R., Kabashima, K., Furue, M., Nakano, M., & Ruzicka, T. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14934 · Cited by 34
Self-citationThe translational revolution of itch
Kim, B. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.031 · Cited by 35
Mast Cell Cytokines in Acute and Chronic Gingival Tissue Inflammation: Role of IL-33 and IL-37
Trimarchi, M., Lauritano, D., Ronconi, G., Caraffa, A., Gallenga, C. E., Frydas, I., Kritas, S. K., Calvisi, V., & Conti, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113242 · Cited by 35
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Trier, A. M., & Kim, B. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac016 · Cited by 33
How to define chronic prurigo?
Pereira, M. P., & Ständer, S. (2019) · Experimental Dermatology · doi:10.1111/exd.13972 · Cited by 31
Lee, H. H., Patel, K. R., Rastogi, S., Singam, V., Vakharia, P. P., Chopra, R., & Silverberg, J. I. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.102 · Cited by 31
Napolitano, M., Ruggiero, A., Fontanella, G., Fabbrocini, G., & Patruno, C. (2020) · Dermatologic Therapy · doi:10.1111/dth.14475 · Cited by 36
Rodríguez, J., Alcantara‐Luna, S., Dominguez‐Cruz, J. J., Galán‐Gutiérrez, M., Ruíz‐Villaverde, R., Vilar-Palomo, S., & Hita, J. C. A. (2021) · Life · doi:10.3390/life11090927 · Cited by 39
Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis
Furue, K., Ulzii, D., Tanaka, Y., Ito, T., Tsuji, G., Kido‐Nakahara, M., Nakahara, T., & Furue, M. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15507 · Cited by 33
Self-citationKołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 39
Novel topical and systemic therapies in atopic dermatitis
Suga, H., & Sato, S. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1642727 · Cited by 33
“Dupilumab IL-4Ra Anti-IL-4Ra mAb Phase III published Regeneron, Tarrytown, NY [35,36] Lebrikizumab IL-13 Anti-IL-13 mAb Phase II published Hoffmann-La Roche, Basel, Switzerland [37] Tralokinumab IL-13 Anti-IL-13 mAb Phase II published MedImmune, Gaithersburg, MD [38] Nemolizumab IL-31R Anti-IL-31R mAb Phase II publish…”
BackgroundIL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
Roh, Y. S., Choi, J., Sutaria, N. H., Belzberg, M., Kwatra, M. M., & Kwatra, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01521-1 · Cited by 31
Current Perspectives on the Systemic Management of Atopic Dermatitis
Davari, D. R., Nieman, E. L., McShane, D. B., & Morrell, D. S. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s287638 · Cited by 34
Serra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.12.014 · Cited by 31
Involvement of Atopic Dermatitis in the Development of Systemic Inflammatory Diseases
Itamura, M., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113445 · Cited by 31
Intractable Itch in Atopic Dermatitis: Causes and Treatments
Umehara, Y., Kiatsurayanon, C., Trujillo-Páez, J. V., Chieosilapatham, P., Peng, G., Yue, H., Nguyen, H. L. T., Song, P., Okumura, K., Ogawa, H., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030229 · Cited by 33
“It has been reported that the humanized anti-human IL-31 receptor A monoclonal antibody CIM331 (nemolizumab) reduces the severity and pruritus score of AD [37,38].”
BackgroundTheoharides, T. C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090860 · Cited by 31
Sekita, A., Kawasaki, H., Fukushima‐Nomura, A., Yashiro, K., Tanese, K., Toshima, S., Ashizaki, K., Miyai, T., Yazaki, J., Kobayashi, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41857-8 · Cited by 36
Hamann, C. R., & Thyssen, J. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.018 · Cited by 30
The pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
Immune mediators and therapies for pruritus in atopic dermatitis and psoriasis
Yu, S., Li, Y., Zhou, Y., Follansbee, T., & Hwang, S. T. (2019) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12049 · Cited by 31
Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate
Stadler, P., Renner, E. D., Milner, J. D., & Wollenberg, A. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.037 · Cited by 32
Self-citationImmunomodulating Agents as Antipruritics
Erickson, S. P., Nahmias, Z. P., Rosman, I. S., & Kim, B. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.014 · Cited by 29
All the small things: How virus‐like particles and liposomes modulate allergic immune responses
Kratzer, B., Hofer, S., Zabel, M., & Pickl, W. F. (2019) · European Journal of Immunology · doi:10.1002/eji.201847810 · Cited by 28
Tauber, M., Wang, F., Kim, B., & Gaudenzio, N. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.03.012 · Cited by 29
Liang, J., Hu, F., Dan, M., Sang, Y., Abulikemu, K., Wang, Q., Hong, Y., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825312 · Cited by 30
“Of the six included studies, there were one phase I trial (15), four phase II trials (16, 18, 28, 29), and one phase III trial (17).”
Yamamoto, Y., Otsuka, A., Nakashima, C., Ishida, Y., Honda, T., Egawa, G., Amano, W., Usui, K., Hamada, Y., Wada, M., et al. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.12.008 · Cited by 26
Self-citationNovel drugs for the treatment of chronic pruritus
Pereira, M. P., & Ständer, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1548606 · Cited by 26
“0 mg per kg of bodyweight, showing robust dose-dependent antipruritic effects compared to placebo [15].”
BackgroundNaidoo, K., Woods, K., Pellefigues, C., Cait, A., O’Sullivan, D., Gell, K., Marshall, A. J., Anderson, R. J., Li, Y., Schmidt, A., et al. (2021) · Allergy · doi:10.1111/all.14994 · Cited by 29
The New Era of Biologics in Atopic Dermatitis: A Review
Schneider, S., Li, L., & Zink, A. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1104a144 · Cited by 28
Werfel, T. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000477 · Cited by 29
Atopic dermatitis as Th2 disease revisited
TOKURA, Y., Phadungsaksawasdi, P., & Ito, T. (2018) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12033 · Cited by 26
Tamamoto‐Mochizuki, C., Paps, J. S., & Olivry, T. (2019) · Veterinary Dermatology · doi:10.1111/vde.12715 · Cited by 38
Uppal, S. K., Kearns, D. G., Chat, V. S., Han, G., & Wu, J. J. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1775775 · Cited by 27
“Treatmentemergent adverse events (TEAEs) were mild to moderate in severity and included exacerbation of AD, nasopharyngitis, upper respiratory tract infection, peripheral edema, and increased creatine kinase levels (47).”
BackgroundInfluentialDupilumab for the Treatment of Atopic Dermatitis
Ferreira, S., & Torres, T. R. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2018.02.019 · Cited by 30
Selective role of neurokinin B in IL-31–induced itch response in mice
Sakata, D., Uruno, T., Matsubara, K., Andoh, T., Yamamura, K., Magoshi, Y., Kunimura, K., Kamikaseda, Y., Furue, M., & Fukui, Y. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.031 · Cited by 25
Self-citationCaffarelli, C., Giannetti, A., Giannì, G., & Ricci, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1214963 · Cited by 27
“Nemolizumab (123–125) (Table 1) has been used in adults with uncontrolled moderate-to-severe AD, has shown to improve pruritus, the primary outcome, sleep score, and EASI in both phase I (126) and II trials (127, 128), with efficacy up to 64 weeks (128).”
BackgroundAdvances in atopic dermatitis in 2017
Kennedy, K. L., Heimall, J. R., & Spergel, J. M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.012 · Cited by 25
Kamata, M., Sun, D. I., & Paller, A. S. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.04.042 · Cited by 27
The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo
Zeidler, C., Pereira, M. P., & Ständer, S. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-00321-6 · Cited by 26
Biologics for Atopic Dermatitis
Boguniewicz, M. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.004 · Cited by 24
Evolving Concepts in Atopic Dermatitis
Sidbury, R., & Khorsand, K. O. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0710-5 · Cited by 28
Chronic Pruritus in the Geriatric Population
Cao, T., Tey, H. L., & Yosipovitch, G. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.004 · Cited by 26
Adult atopic dermatitis: new and emerging therapies
Napolitano, M., Marasca, C., Fabbrocini, G., & Patruno, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1507734 · Cited by 25
Dhadwal, G., Albrecht, L. E., Gniadecki, R., Poulin, Y. P., Yeung, J., Hong, C.-H., & Gooderham, M. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418805721 · Cited by 25
“trial results show significant improvements in pruritus in patients with AD but not in Eczema Area and Severity Index (EASI) scores.(63) Fezakinumab targets IL-22, which is thought to play a role in barrier function and may be an important target in specific AD populations.”
Cutaneous Adverse Events Following Nemolizumab Administration: A Review
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093026 · Cited by 23
“These lesions typically present in a symmetrical distribution across the limbs and trunk [31,32].”
Roy, Y. R. L., Ficheux, A., Misery, L., & Brenaut, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1079323 · Cited by 28
“0 mg/kg every 8 weeks (264 patients included) (56).”
BackgroundTreatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study
Todberg, T., Zachariae, C. O. C., & Skov, L. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3471 · Cited by 23
Pantazi, E., Valenza, G., Hess, M., & Hamad, B. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.192 · Cited by 24
Rademaker, M., Agnew, K., Andrews, M., Baker, C., Foley, P. A., Gebauer, K., Gupta, M., Rubel, D. M., Somerville, C., Sullivan, J. R., et al. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.13141 · Cited by 25
Richards, C. D., Gandhi, R., Botelho, F. M., Ho, L., & Paolini, J. F. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3505 · Cited by 23
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Waligóra-Dziwak, K., Dańczak‐Pazdrowska, A., & Jenerowicz, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144001 · Cited by 23
Advances in atopic dermatitis and urticarial in 2016
Honda, T., Nomura, T., & Kabashima, K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.005 · Cited by 25
Self-citationTherapeutic strategies for eosinophilic dermatoses
Simon, D., & Simon, H. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.002 · Cited by 24
Sevagamoorthy, A., Sockler, P. G., Akoh, C. C., & Takeshita, J. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2114783 · Cited by 22
Molina, P., Ojeda, R., Blanco, A., Bezhold, G. A., Prieto‐Velasco, M., Aresté-Fosalba, N., Buades, J. M., Simó, V. E., Goicoechea, M., Pérez-Morales, R. E., et al. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.03.015 · Cited by 27
Alexander, H., Patton, T., Jabbar‐Lopez, Z. K., Manca, A., & Flohr, C. (2019) · F1000Research · doi:10.12688/f1000research.17039.1 · Cited by 25
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 23
Nakagawa, Y., & Yamada, S. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001482 · Cited by 20
The evolving atopic dermatitis management landscape
Sahni, V. N., Balogh, E. A., Strowd, L. C., & Feldman, S. R. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999412 · Cited by 20
Atopic dermatitis: a review of evolving targeted therapies
Kalamaha, K., Reis, E., Newton, S. L., Roche, C., Julson, J. R., Fernandes, H., & Rodrigues, J. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1560267 · Cited by 21
“Nemolizumab (CIM331) is another SC or IV administered IL31 mAb acting on the IL-31 receptor A [39,64].”
BackgroundCurrent and emerging biologic and small molecule therapies for atopic dermatitis
Li, R., Hadi, S. M., & Guttman‐Yassky, E. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1573422 · Cited by 22
“01) in pruritus scores from baseline for nemolizumab (~60%) compared to placebo (~21%) [75].”
BackgroundLü, P., Wu, F. ‐., Rong, Z., Fang, C., Deng, C., Bin, L., & Yang, B. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.13925 · Cited by 20
Hu, M., Scheffel, J., Komi, D. E. A., Maurer, M., Hawro, T., & Metz, M. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01141-x · Cited by 21
American Academy of Dermatology Annual Meeting: Orlando, FL, USA, 3–7 March 2017
Fraser, K. A. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0273-1 · Cited by 20
Current treatment strategies in refractory chronic pruritus
Pereira, M. P., Mittal, A. K., & Ständer, S. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.11.007 · Cited by 20
A new era has begun: Treatment of atopic dermatitis with biologics
Stölzl, D., Weidinger, S., & Drerup, K. A. (2021) · Allergologie select · doi:10.5414/alx02259e · Cited by 22
Neuroimmune Circuits in Allergic Diseases
Cai, H., Zhu, X., & Sokol, C. L. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-032154 · Cited by 19
Pathogenese des atopischen Ekzems
Scheerer, C., & Eyerich, K. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4127-4 · Cited by 23
A case of bullous pemphigoid following administration of anti‐IL ‐31 receptor A antibody
Masuyuki, R., Sato, E., & Imafuku, S. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17171 · Cited by 19
Nocchi, L., Roy, N., D’Attilia, M., Dhandapani, R., Maffei, M., Traista, A., Castaldi, L., Perlas, E., Chadick, C. H., & Heppenstall, P. A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0328-5 · Cited by 22
Morais, K. L., Miyamoto, D., Orfali, R. L., Maruta, C. W., Santi, C. G., Sotto, M. N., da Silva, L. F. F., Branco, A. C. C. C., Sato, M. N., & Aoki, V. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16730 · Cited by 21
Neural Regulation of Innate Immunity in Inflammatory Skin Diseases
Huang, X., Li, F., & Wang, F. (2023) · Pharmaceuticals · doi:10.3390/ph16020246 · Cited by 20
Biologic and Small Molecule Therapy in Atopic Dermatitis
Shergill, M., Bajwa, B., Yilmaz, O., Tailor, K., Bouadi, N., & Mukovozov, I. (2024) · Biomedicines · doi:10.3390/biomedicines12081841 · Cited by 20
“In particular, XCIMA, a phase II trial, described significant changes on the pruritus visual analogue scale, at − 43.7% in the 0.1 mg/kg group, − 59.8% in the 0.5 mg/kg group, and − 63.1% in the 2.0 mg/kg group, versus − 20.9% in the placebo group at week 12 [53].”
BackgroundInfluentialNovel Therapeutic Approaches to Atopic Dermatitis
Osinka, K., Dumycz, K., Kwiek, B., & Feleszko, W. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0487-1 · Cited by 19
Therapy for pruritus in the elderly: a review of treatment developments
Pereira, M. P., & Ständer, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1444752 · Cited by 21
Investigational drugs for atopic dermatitis
Hon, K. E., Leung, A. K. C., Leung, T. N., & Lee, V. W. Y. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494723 · Cited by 18
Emerging Treatments and Novel Pathways in Pruritus
Morin, C. B., & Misery, L. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419852050 · Cited by 19
Nakahara, T., Izuhara, K., Onozuka, D., Nunomura, S., Tamagawa‐Mineoka, R., Masuda, K., Ichiyama, S., Saeki, H., Kabata, Y., Abe, R., et al. (2020) · Medicine · doi:10.1097/md.0000000000022043 · Cited by 21
“Other lesional and blood markers including eosinophils, lactate dehydrogenase (LDH),([14]) total immunoglobulin E (IgE),([15]) soluble IL-2 receptor,([16]) CCL27,([14]) IL-13,([17]) IL-22,([9]) IL24,([18,19]) IL-25,([20]) IL-31,([21,22]) IL-33,([23]) thymic stromal lymphopoietin (TSLP),([24]) periostin,([9,25]) and sq…”
BackgroundSelf-citationA New Era with the Development of Cytokine-Based Therapy for Pruritus
Shibuya, R., Takimoto‐Ito, R., Kambe, N., & Kabashima, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.023 · Cited by 20
“Multiple clinical trials have now demonstrated the antipruritic effect of nemolizumab, a humanized anti-human IL-31RA mAb, for patients with AD (Kabashima et al., 2020, 2018; Nemoto et al., 2016; Ruzicka et al., 2017; Silverberg et al., 2020a).”
BackgroundSelf-citationIs there still a role for UV therapy in itch treatment?
Legat, F. J. (2019) · Experimental Dermatology · doi:10.1111/exd.14011 · Cited by 19
IL-31/33 Axis in Atopic Dermatitis
Łacwik, J., Kraik, K., Laska, J., Tota, M., Sędek, Ł., & Gomułka, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010162 · Cited by 20
Shin, H., Lee, S. H., Yoon, H. S., Heo, J. H., Lee, S. B., Byun, J. W., Shin, J., Cho, Y., Chung, E., Jeon, M., et al. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15928 · Cited by 20
Rook, A. H., Rook, K. A., & Lewis, D. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55617-4_8 · Cited by 17
Qi, H.-J., & Li, L. (2021) · BioMed Research International · doi:10.1155/2021/5528372 · Cited by 19
Tietz, J., Gunde, T., Warmuth, S., Weinert, C., Brock, M., Simonin, A., Hess, C., Johansson, M., Spiga, F., Muntwiler, S., et al. (2024) · JID Innovations · doi:10.1016/j.xjidi.2024.100258 · Cited by 16
Chen, S., Li, C., Tu, Z., Cai, T., Zhang, X., Wang, L., Tian, R., Huang, J., Gong, Y., Yang, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1324892 · Cited by 16
Novel therapies based on the pathophysiology of atopic dermatitis
Bieber, T. R. M. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13965 · Cited by 23
Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence
Husein‐ElAhmed, H., & Steinhoff, M. S. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1914315 · Cited by 17
Li, A., Zhang, M., Yang, Y., Zhang, J. H., Xie, X., Li, X., & Zhang, H. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3164 · Cited by 16
Future trends in the treatment of atopic dermatitis
Igawa, K. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1628467 · Cited by 19
“In two recent phase II trials, in adult patients with refractory moderate to severe AD there were reportedly dramatic reductions in pruritus in conjunction with improvement of clinical signs of AD, as compared with the placebo group [33,34].”
BackgroundHonstein, T., & Werfel, T. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000652 · Cited by 17
“The initial evaluation of a study of 12 weeks on 216 patients showed major effects on the reduction of pruritus [31].”
Background
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.